MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Официальное название

A Single Arm, Open-label Study of MRD-Guided Zanubrutinib in Combination With Sonrotoclax in Adult Patients With Treatment Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Обзор

This is a single-arm, open-label study of sonrotoclax plus zanubrutinib with MRD-driven treatment duration in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The primary goal of this study is to evaluate the efficacy of MRD-guided zanubrutinib plus sonrotoclax for first-line CLL/SLL treatment.

Подробное описание

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are often considered different variations of the same disease due to their many similarities. There is an urgent need for new treatments to improve patients' quality of life, prolong survival, and manage disease-related symptoms.

There are several different methods for treating front-line therapy, including Chemoimmunotherapy (CIT), Bruton tyrosine kinase inhibitors (BTKis), and BCL-2 inhibitors (BCL2is). Continuous treatment with BTK inhibitors is necessary for the treatment of CLL or SLL. However, younger patients may need to limit their therapeutic duration. The combination of BTK inhibitors and BCL-2 inhibitors is believed to be an optimizing regimen that provides a limited duration of therapy.

The main aim of this study is to assess whether MRD-guided zanubrutinib, in combination with sonrotoclax, can be an effective first-line treatment option for adult patients with treatment-naïve CLL or SLL. The goal is to achieve long-lasting and more profound responses, which could allow for the possibility of discontinuing treatment.

Вмешательства

• Препарат Sonrotoclax
  Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days). Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR. Participants will receive sonrotoclax up to 2 years, and receive zanub
• Препарат Zanubrutinib
  Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR. Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.

Первичные конечные точки

• 4-Year Progressive Free Survival (PFS) Rate [Срок оценки: 4 years after enrollment]

Вторичные конечные точки (8)

• Rate of peripheral blood (PB) and Bone marrow (BM) undetectable minimal residual disease (uMRD) [Срок оценки: At screening, the end of Cycle 14 and Cycle 26 (each cycle is 28 days)]
• Complete Response Rate (CRR; Complete Response/Complete Response with Incomplete Blood Count Recovery [CR/CRi]) Rate [Срок оценки: Up to 4 years]
• Overall Response Rate (ORR) [Срок оценки: Up to 4 years]
• Duration of Response (DOR) [Срок оценки: Up to 4 years]
• Progression Free Survival (PFS) [Срок оценки: Up to 4 years]
• Overall Survival (OS) [Срок оценки: Up to 4 years]
• Time to Next Therapy (TTNT) [Срок оценки: Up to 4 years]
• Overall survival rate [Срок оценки: Up to 4 years]

Критерии участия

Критерии включения

• Treatment naïve adult patients with diagnosis of CLL/SLL requiring treatment according to iwCLL guidelines 2018
• Measurable nodal disease by CT/MRI.
• Adequate hematologic function
• Adequate hepatic and renal function
• Eastern Cooperative Oncology Group
• (ECOG) performance status of 0-2
• Expected survival period > 6 months

Критерии исключения

• Any prior systemic therapy used for treatment of CLL/SLL
• With history of prolymphocytic leukemia, known or currently suspected Richter's transformation
• Known central nervous system involvement by leukemia or lymphoma
• Confirmed progressive multifocal leukoencephalopathy (PML)
• Severe or debilitating pulmonary disease
• Clinically significant cardiovascular disease
• Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura requiring treatment
• History of other malignancies
• Prior therapy with study drugs within 4 weeks before screening
• Active fungal, bacterial, and/or viral infection requiring systemic therapy
• Known allergy to zanubrutinib or sonrotoclax or any pharmaceutical excipients
• Pregnant or lactating women
• Vaccinated with live vaccines within 28 days prior to enrollment
• Serologically positive of human immunodeficiency virus (HIVAb), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
• History of stroke or intracranial hemorrhage within 6 months
• Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06367374 · BGB-11417-2002-IIT；BDH-CLL-004

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗